Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Pfizer initiates phase II study of PF-06700841 topical cream for atopic dermatitis

June 6, 2019

Aslan reports final results from single-ascending-dose study of ASLAN-004

June 5, 2019

Arcutis begins phase IIa trial of ARQ-151 in atopic dermatitis

June 5, 2019

First patient dosed in B-SIMPLE phase III program of SB-206

June 5, 2019

Dermavant Sciences initiates phase III study of tapinarof for the treatment of plaque psoriasis

June 3, 2019

Patient recruitment ongoing in phase I study of BOS-475

May 31, 2019

Results of phase IIb trial of topical PAC-14028, a TRPV1 antagonist, in atopic dermatitis

May 28, 2019

Aclaris Therapeutics patents JAK1 and JAK3 inhibitors

May 27, 2019

Toray Industries divulges RORC antagonists

May 22, 2019

FLX Bio presents a novel CCR4 antagonist for the treatment of allergic disorders

May 21, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...